Minimal residual disease (MRD) refers to the small population of cancer cells that survive initial therapy and may cause relapse. Detecting and understanding MRD is critical for improving long-term outcomes in blood cancers. Genetically modified blood cancer models expressing fluorescent or luminescent reporter genes allow researchers to sensitively track residual tumor cells in vivo and…
Oncogenic fusion proteins, resulting from chromosomal translocations, are hallmark drivers of many hematologic malignancies. These fusion proteins often function as aberrant transcription factors or kinases, promoting uncontrolled cell growth and survival. Targeting them is a promising therapeutic strategy. RNA interference (RNAi) techniques, including siRNA and shRNA, enable selective silencing of fusion gene transcripts by designing…
Gene knockdown via RNA interference (RNAi) is a common method to study gene function by reducing target gene expression. Accurate validation of knockdown efficiency in leukemia cell lines following transfection is crucial to ensure experimental reliability. Validation begins at the mRNA level, where quantitative real-time PCR (qRT-PCR) measures the relative reduction of target transcript abundance…
Flow cytometry is a powerful analytical technology widely used in blood cancer research to evaluate cellular characteristics on a single-cell basis. This technique is invaluable for assessing transfection efficiency, cell viability, and phenotypic changes in both in vitro and in vivo studies. In transfection experiments, flow cytometry allows researchers to quantify the proportion of cells…
In vivo models, particularly xenografts, are indispensable in translating laboratory discoveries into effective clinical therapies for blood cancers. These models provide critical insights that shape the design, dosing, and patient selection criteria of clinical trials. Preclinical testing in animal models assesses not only the efficacy of novel compounds but also their toxicity, metabolism, and interaction…
The success of electroporation—a leading method for transfecting suspension blood cancer cells—depends not only on electrical parameters but also critically on the composition of the electroporation buffer. This often underappreciated factor can dramatically influence transfection efficiency and cell viability. Electroporation buffers serve multiple purposes. They maintain ionic strength and osmolarity compatible with cell survival while…
Messenger RNA (mRNA) transfection has emerged as a powerful tool in leukemia research and therapeutic development, offering a transient, non-integrative means to express proteins of interest. Unlike DNA plasmid transfection, mRNA does not require nuclear entry and thus produces protein expression rapidly, reducing the risk of insertional mutagenesis and off-target genomic effects. In leukemia therapy…
Selecting an appropriate cell line is a foundational step in lymphoma research, impacting experimental design, transfection strategies, and data interpretation. Among the most commonly used Burkitt’s lymphoma cell lines are Raji, Ramos, and Daudi, each with unique characteristics suitable for different research applications. Raji cells were derived from a Burkitt’s lymphoma patient and express high…
The combination of advanced gene delivery methods, such as transfection, with immunotherapy research has opened exciting new horizons for treating blood cancers. Immunotherapy harnesses the patient’s immune system to target and eliminate malignant cells, often through engineered immune cells or immune checkpoint modulation. Transfection techniques allow scientists to genetically modify immune cells, such as T…
Xenograft models play a pivotal role in the preclinical development pipeline for blood cancer therapies, serving as an essential bridge between in vitro research and human clinical trials. The U.S. Food and Drug Administration (FDA) requires robust preclinical data to assess the safety, efficacy, and pharmacokinetics of new drugs before approving their progression into clinical…
